GEN secures BEBO Foundation approval for Phase II PD trial
The study will assess the effects of SUL-238 on high energy phosphates using 31P-MRS in PD patients.
17 March 2026
17 March 2026
The study will assess the effects of SUL-238 on high energy phosphates using 31P-MRS in PD patients.
The AI lung digital twin platform is built upon NVIDIA’s physical AI infrastructure.
Sentynl will acquire full rights to Progerinin for HGPS, provided certain milestones are achieved.
The certification expands access to Freedom60 and FreedomEDGE infusion pumps for growing SCIg prefilled syringe use.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.